CCO Independent Conference Coverage
2009 Conference on Retroviruses and Opportunistic Infections*
February 8-11, 2009 | Montreal, Canada
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Management of Antiretroviral-Naive Patients
|
Track 1 of 3
|
|
|
|
   |
- Joel E. Gallant, MD, MPH
- W. David Hardy, MD
- Kathleen E. Squires, MD
|
|
|
Resistance and Management of Treatment-Experienced Patients
|
Track 2 of 3
|
|
|
|
   |
- Eric S. Daar, MD
- Joseph J. Eron, Jr., MD
- Kimberly Y. Smith, MD, MPH
|
|
|
HIV Highlights From Montreal
|
Track 3 of 3
|
Expert Highlights
Switch Studies From Lopinavir/Ritonavir to Raltegravir
Now Playing...
Kimberly Y. Smith, MD, MPH, describes these interesting results from the SWITCHMRK trial.
When to Start
Now Playing...
Joel E. Gallant, MD, MPH, reviews results from NA-ACCORD, the ART Cohort Collaboration, that provide additional data to consider when determining when to initiate antiretroviral therapy.
Mouse over thumbnails for more information on the segments
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
EASIER: Randomized Trial Confirms Efficacy and Safety of Switching From Enfuvirtide to Raltegravir in Virologically Suppressed Patients With Multidrug-Resistant HIV
In this randomized, open-label trial, patients with virologic suppression on an enfuvirtide-based regimen maintained suppression at 24 weeks after switching to raltegravir with no significant differences in laboratory abnormalities or adverse events vs patients who stayed on enfuvirtide.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|
|